Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy

World Journal of Urology

Volumn 32, Issue 5, 2014, Pages 1339-1345

  Komura, Kazumasa ^a   Inamoto, Teruo ^a   Takai, Tomoaki ^a   Uchimoto, Taizo ^a   Saito, Kenkichi ^a   Tanda, Naoki ^a   Kono, Junko ^a   Minami, Koichiro ^a   Uehara, Hirohumi ^a   Fujisue, Yutaka ^a   Takahara, Kiyoshi ^a   Hirano, Hajime ^a   Nomi, Hayahito ^a   Watsuji, Toshikazu ^b   Kiyama, Satoshi ^a   Azuma, Haruhito ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Hirakata City Hospital   (Japan)

Author keywords

HIFU; Localized prostate cancer; Outcome; Single session treatment

Indexed keywords

EID: 84887960475     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1215-z     Document Type: Article

References (20)

1. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123
2. Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A (2008) First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 53:1194–1201
3. Crouzet S, Rebillard X, Chevallier D, Rischmann P, Pasticier G, Garcia G, Rouviere O, Chapelon JY, Gelet A (2010) Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 58:559–566
4. Ganzer R, Robertson CN, Ward JF, Brown SC, Conti GN, Murat FJ, Pasticier G, Rebillard X, Thuroff S, Wieland WF, Blana A (2011) Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria—analysis from the @-Registry. BJU Int 108:E196–E201
5. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL (2003) Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57:915–928
6. Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, Ward JF (2009) High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 104:1058–1062
7. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974
8. Pfeiffer D, Berger J, Gross AJ (2012) Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes. BJU Int 110:1702–1707
9. Pinthus JH, Farrokhyar F, Hassouna MM, Woods E, Whelan K, Shayegan B, Orovan WL (2012) Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology. BJU Int 110:1142–1148
10. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974
11. National Comprehensive Cancer Network (2004) Prostate cancer. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2:224–248
12. American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035–1041
13. Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL (2005) Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 173:797–802
14. Patel A, Dorey F, Franklin J, deKernion JB (1997) Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158:1441–1445
15. Richaud P, Moreau JL, Beuzeboc P, Rebillard X, Villers A, Peyromaure M, Cornud F, Soulie M, Davin JL (2005) Follow-up of prostate cancer. Guidelines of the Comite de Cancerologie de l’Association Francaise d’Urologie. Prog Urol 15:586–592
16. Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF, Blana A (2008) PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol 53:547–553
17. Uchida T, Illing RO, Cathcart PJ, Emberton M (2006) To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 98:537–539
18. Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A (2007) Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer 110:68–80
19. Zelefsky MJ, Shi W, Yamada Y, Kollmeier MA, Cox B, Park J, Seshan VE (2009) Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys 75:1350–1356
20. Rebillard X, Soulie M, Chartier-Kastler E, Davin JL, Mignard JP, Moreau JL, Coulange C (2008) High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 101:1205–1213